The Effect of Intravitreal Ranibizumab Application at Two Different Concentrations on Threshold Retinopathy of Prematurity
Damla Ergintürk ACAR1, Mehmet Cüneyt ÖZMEN2, Özdemir ÖZDEMİR1, Zuhal Özen TUNAY1, Uğur ACAR3
Intravitreal anti-vascular endothelial growth factor was decided to perform to a premature boy who was born at 26 weeks gestational age weighing 870 g, upon detection of bilateral zone 2 posterior, stage 2 retinopathy of prematurity (ROP) with plus disease in ophthalmic examination with binocular indirect ophthalmoscopy of him at postconceptual age of 33 weeks. Intravitreal semi-dose (0.25 mg/0.025 ml) ranibizumab was administered to the right eye of premature infant. After one day, quarter dose (0.125 mg/0.0125 ml) was administered to the left eye because of incorrect dose adjustment of drug. At third day of treatment, plus disease recovered. However, we performed diod laser photocoagulation bilaterally, because of plus disease and zone 2, stage 3 ROP were determined after 4 weeks of initial intravitreal ranibizumab treatment. At second week of laser treatment, plus disease disappeared again. He has been followed up for 9 months and no ocular or systemic side effect was identified.
Anti-vascular endothelial growth factor, ranibizumab, retinopathy of prematurity